Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 3

Withdrawn

Conditions: Diabetic Macula Edema

Interventions: Drug: Aflibercept
Drug: Brolucizumab

First Posted Date: 2019-09-06

Last Posted Date: 2021-03-04

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04079231

Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

Phase 2

Terminated

Conditions: Colitis, Ulcerative

Interventions: Drug: Placebo
Drug: LYS006

First Posted Date: 2019-08-30

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT04074590

Locations: 🇸🇰
Novartis Investigative Site, Kosice, Slovakia

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: KAF156
Drug: Placebo

First Posted Date: 2019-08-28

Last Posted Date: 2019-08-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 86

Registration Number: NCT04072302

Locations: 🇺🇸
Novartis Investigative Site, Seattle, Washington, United States

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: QBW251
Drug: Placebo
Drug: COPD maintenance background therapy

First Posted Date: 2019-08-28

Last Posted Date: 2023-04-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 974

Registration Number: NCT04072887

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: BLZ945

First Posted Date: 2019-08-26

Last Posted Date: 2024-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT04066244

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden
🇺🇸
Massachusetts General Hospital ., Boston, Massachusetts, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

Phase 2

Terminated

Conditions: Non Alcoholic Steatohepatitis (NASH)

Interventions: Other: Placebo
Drug: Tropifexor
Drug: Licogliflozin

First Posted Date: 2019-08-22

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 234

Registration Number: NCT04065841

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Phase 2

Completed

Conditions: Pulmonary Sarcoidosis

Interventions: Drug: CMK389
Drug: Placebo

First Posted Date: 2019-08-21

Last Posted Date: 2024-10-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT04064242

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
Univ of Florida College of Medicine x, Gainesville, Florida, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

and more 4 locations

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: PDR001

First Posted Date: 2019-08-16

Last Posted Date: 2024-11-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT04058756

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center Uni of Te, Houston, Texas, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

and more 1 locations

To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Brolucizumab
Drug: Aflibercept

First Posted Date: 2019-08-15

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 263

Registration Number: NCT04058067

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: Crizanlizuamb
Drug: Standard of Care

First Posted Date: 2019-08-12

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT04053764

Locations: 🇺🇸
Univ of Tenn Health Sciences Ctr, Memphis, Tennessee, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
University of Illinois Hospital and Health Sciences System ., Chicago, Illinois, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy